ECG / EKG in Massachusetts

Zoe Medical, Inc. is a US-based manufacturer of patient monitoring systems founded in 1996 and headquartered 30 miles north of Boston in Topsfield, Massachusetts. The company has established itself as one of the largest patient monitoring system manufacturers in the United States, with tens of thousands of installed units globally. Zoe designs, manufactures, and supports all products domestically in the USA. Historically, Zoe has operated primarily as an OEM/contract manufacturer for major healthcare organizations. The company now distributes its own-label monitoring products at factory-direct pricing, targeting physician offices, oral and outpatient surgery centers, emergency medical services (EMS), and central monitoring stations. Product portfolio includes the Nightingale series (PPM3 for oral/outpatient surgery, PHM compact spot-check monitor with thumb ECG for physician offices, and MPC nurse central station for alarm surveillance and trending) and the 740SELECT multiparameter monitor for EMS and vital signs applications. All monitors support standard vital sign parameters including ECG, blood pressure, pulse oximetry, temperature, and capnography. The company emphasizes substantial R&D investment, proprietary product architecture, and manufacturing capability. Products are designed for clinical environments ranging from point-of-care physician offices to operating rooms, EMS transport, and hospital central monitoring. Zoe maintains direct customer support and offers sales quotes and customized solutions. All manufacturing and technical support are US-based.

InfoBionic, Inc. is a virtual cardiac telemetry company specializing in AI-enabled remote cardiac monitoring. The company's flagship product, MoMe ARC® (Advanced Remote Cardiology), is recognized as the gold standard in remote cardiac ECG monitoring and represents the first platform to market with hospital-grade continuous monitoring capability deployable from nearly any location. The MoMe ARC® platform integrates advanced artificial intelligence to enhance clinical workflow, detect previously undetected cardiac anomalies, and enable rapid interventions at scale. InfoBionic offers a comprehensive suite comprising MoMe Solutions (AI-enabled ECG analysis), MoMe Sensors (interchangeable, tiered biosensor lead sets configurable for varying acuity levels from high-acuity diagnostics to portable monitoring), and MoMe Analytics™ (business intelligence and AI-embedded analytics for cardiac care operations). The company targets cardiology practices, cardiologists, electrophysiologists, medical leaders, hospital systems, and virtual health programs. InfoBionic has received FDA clearance for its MoMe ARC® Patch (announced August 2025), affirming regulatory compliance and clinical safety. The platform transforms cardiac data into actionable clinical insight through proprietary AI algorithms focused on arrhythmia detection, atrial fibrillation monitoring, and congenital heart disease assessment. Products are designed to improve patient quality of life through earlier interventions, enhance operational efficiency across departments, and support both enterprise and telehealth deployment models.

Anumana Inc. is a cardiovascular AI software company headquartered in Cambridge, MA, developing FDA-cleared algorithms for ECG analysis and cardiac disease detection. Founded in 2021 as a joint effort between Mayo Clinic and nference, the company specializes in ECG-AI®, a proprietary platform that analyzes 12-lead electrocardiograms using deep learning to identify cardiac pathology invisible to clinicians. The flagship algorithm detects low ejection fraction (LEF) and is clinically validated on approximately 2.9 million ECG-echo pairs from 676,000+ patients across diverse populations. The platform has received FDA 510(k) clearance (K250652) for LEF detection and recent clearances for cardiac amyloidosis and pulmonary hypertension algorithms. Anumana's technology integrates seamlessly into existing EHR systems and ECG management platforms without requiring external data processing—algorithms run on-premises for enhanced data security and privacy. The company's AI engine processes 60,000 ECG data points per study and delivers clinical findings compatible with current cardiology workflow. Product portfolio includes multiple cardiac-focused algorithms in development spanning early disease detection, perioperative imaging, atrial fibrillation risk stratification, hyperkalemia detection, diastolic dysfunction assessment, and cardiomyopathy screening. Clinical evidence published across 100+ peer-reviewed publications in journals including Nature Medicine, JACC, and European Heart Journal. The platform supports EHR orderable creation, HL7 configuration, CPT code assignment, and is eligible for reimbursement in US and EU markets. Anumana serves cardiology practices, hospitals, and integrated health systems seeking AI-assisted ECG interpretation and early identification of at-risk cardiac patients.

Whoop, Inc. manufactures WHOOP, a 24/7 wearable health monitoring device designed for personal wellness, fitness optimization, and recovery tracking. The device combines continuous heart rate monitoring, sleep analysis, strain/recovery quantification, and stress monitoring via screen-free wrist-worn sensors that collect data every second. WHOOP offers three tiered membership levels (One, Peak, Life) with increasingly advanced features including VO2 Max tracking, heart rate zones, women's hormonal cycle insights, blood pressure monitoring (beta), ECG readings, and atrial fibrillation detection. The platform emphasizes personalized coaching and behavioral insights tied to sleep duration, physical activity, and recovery metrics. Advanced Labs is an ancillary service offering 65+ biomarker analysis integrated with 24/7 wearable data. The WHOOP 5.0 and WHOOP MG devices feature 14+ day battery life, waterproof design, and customizable wear options (leather, sport, flex, apparel). Target market spans consumer fitness enthusiasts, athletes, and wellness-focused individuals. Membership is HSA/FSA eligible. ECG and blood pressure features carry age and medical contraindications; advanced monitoring features are medically regulated and region-restricted. The company emphasizes data privacy and clinician-reviewed results.

Implicity is a cloud-based digital MedTech software company specializing in AI-driven remote cardiac monitoring and research solutions for healthcare providers. Founded in 2016, the platform centralizes and standardizes cardiac implantable electronic device (CIED) data from multiple manufacturers (Abbott, Biotronik, Boston Scientific, Medtronic, Microport) into a single unified dashboard. The FDA-cleared, CE-marked platform employs patented AI algorithms to filter clinical alerts, reduce false positives by up to 79%, and prioritize clinically relevant events for faster clinical decision-making. Key solutions include vendor-neutral CIED remote monitoring, ILR ECG Analyzer (for Medtronic implantable loop recorders), AF Alert Management, SignalHF Predictive AI for heart failure risk stratification, and advanced research tools for real-time clinical data collection. The platform demonstrates proven clinical impact: 26% reduction in mortality, 4% reduction in hospitalization length, and 85% reduction in unnecessary atrial fibrillation alerts. Implicity serves over 100,000 patients across more than 250 medical facilities in the United States and Europe, with offices in Cambridge, Massachusetts, and Paris, France.